Form 8-K - Current report:
SEC Accession No. 0001641172-25-008988
Filing Date
2025-05-07
Accepted
2025-05-07 11:00:08
Documents
19
Period of Report
2025-05-07
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 48074
2 EX-3.1 ex3-1.htm EX-3.1 10784
3 EX-99.1 ex99-1.htm EX-99.1 12747
4 GRAPHIC ex99-1_002.jpg GRAPHIC 9296
5 GRAPHIC ex99-1_001.jpg GRAPHIC 12313
6 GRAPHIC form8-k_001.jpg GRAPHIC 5694
  Complete submission text file 0001641172-25-008988.txt   346129

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE cycc-20250507.xsd EX-101.SCH 3744
8 XBRL DEFINITION FILE cycc-20250507_def.xml EX-101.DEF 26582
9 XBRL LABEL FILE cycc-20250507_lab.xml EX-101.LAB 36614
10 XBRL PRESENTATION FILE cycc-20250507_pre.xml EX-101.PRE 25206
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5867
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 25919919
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)